Atlas Trials

Hebei Yanda Ludaopei Hospital

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Hebei Yanda Ludaopei Hospital

RecordFirmDate
Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients (NCT05590091)Hebei Yanda Ludaopei Hospital2022-11-01
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05518357)Hebei Yanda Ludaopei Hospital2022-06-24
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (NCT04508842)Hebei Yanda Ludaopei Hospital2020-10-10
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (NCT04412174)Hebei Yanda Ludaopei Hospital2020-06-01
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM (NCT04412889)Hebei Yanda Ludaopei Hospital2020-06-01
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (NCT04260945)Hebei Yanda Ludaopei Hospital2020-03-10
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (NCT04260932)Hebei Yanda Ludaopei Hospital2020-03-01
EBV-TCR-T Cells for EB Virus Infection After HSCT (NCT04156217)Hebei Yanda Ludaopei Hospital2020-02-10
CMV-TCR-T Cells for CM Virus Infection After HSCT (NCT04153279)Hebei Yanda Ludaopei Hospital2019-12-19
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT04129099)Hebei Yanda Ludaopei Hospital2019-10-22
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (NCT03953599)Hebei Yanda Ludaopei Hospital2019-07-01
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825731)Hebei Yanda Ludaopei Hospital2019-01-17
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825718)Hebei Yanda Ludaopei Hospital2019-01-17
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT03751293)Hebei Yanda Ludaopei Hospital2019-01-08

Track Hebei Yanda Ludaopei Hospital automatically

Every clearance here is in the API, with alerts when new ones post.